Compare SVM & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | ADMA |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2005 | 2012 |
| Metric | SVM | ADMA |
|---|---|---|
| Price | $12.92 | $10.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.50 | ★ $28.00 |
| AVG Volume (30 Days) | 4.1M | ★ 9.5M |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $42,219,783.00 |
| Revenue This Year | $36.87 | $27.46 |
| Revenue Next Year | $35.34 | $22.11 |
| P/E Ratio | ★ N/A | $17.87 |
| Revenue Growth | N/A | ★ 43.85 |
| 52 Week Low | $3.48 | $7.21 |
| 52 Week High | $14.00 | $25.67 |
| Indicator | SVM | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 45.12 |
| Support Level | $9.73 | $7.21 |
| Resistance Level | $13.99 | $16.61 |
| Average True Range (ATR) | 0.61 | 0.48 |
| MACD | 0.26 | 0.37 |
| Stochastic Oscillator | 84.41 | 90.42 |
Silvercorp Metals Inc is a mineral exploration company, engaged in the acquisition, exploration, development, and mining of mineral properties. The company's producing mines are located in China, and exploration and development projects are located in China and Ecuador. Its project portfolio comprises the El Domo copper-gold and the Condor gold project in Ecuador. In addition, it operates several silver-lead-zinc mines at the Ying Mining District in Henan Province, China, and the GC silver-lead-zinc mine in Guangdong Province, China. A majority of the company's revenue is generated through the sale of silver concentrates. Its reportable operating segments are the Ying Mining District and GC Mine in China, which derive maximum revenue, and the El Domo and Condor projects in Ecuador.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.